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Abstract: Reaction of epoxides 1 and 2 with 2-aminobenzimidazole led to formation of imidazobenzimidazol-2-ones 
4  and  pyrimido[1,2-a]benzimidazol-2,3-diones  5,  respectively  in  good  yields.  This  same  compound  5  may  be 
obtained by another route by reacting halohydrin derivates 3 with 2-aminobenzimidazole. The mechanisms of the 
studied reactions are discussed. 
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Introduction 
 
Benzimidazole  derivatives  belong  to  a  crucial  structural  motif  that  is  seen  in  many 
pharmaceutical and biologically interesting molecules
1.Some of their analogous show an array of 
biological activities, including nonnucleoside HIV-1 reverse transcriptase inhibitors
2, they are 
selective inhibitors of cyclooxygenase-Cox-2
3, and they are resistance in Trichostrongylus axe in 
sheep
4.  Several  benzimidazoles  have  been  reported  as  antiviral
5,  anticoagulant
6,  anti-
inflammatory
7, antibacterial
8, anticancer
9 and antiproliferatif agents
10. 
Moreover heterocycles derivatives of benzimidazoles systems have been tested as a potential 
antimicrobial
11,  antibacterial
12,  antimalarial
13,  antineoplastic
14,  antioxidant
15,  antidiabetic
16,
 
anticonvulsant
16  and anti-hepatitis C virus agents
17.
 
Therefore, the widespread importance of benzimidazole structure has prompted extensive studies 
for practical synthetic methods to access to this class of heterocycles
18.
 
  The  preparation  and  investigation  of  bioactive  nitrogen,  oxygen  and  sulfur  containing 
heterocycles is one of our ongoing projects. We have already developed some procedures to gain 
access to diverse structures as benzodiazepines
19, triazoles, triazolopyrimidines, benzimidazoles 
and imidazoles
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In continuation of our interest in the synthesis of novel polyfunctionalized heterocycles of 
biological importance, we report here an easy one-pot synthesis of the novel compounds via the 
reaction  of  cyanoepoxides  1,  epoxides  cyanoesters  2  and  halohydrins  3  respectively,  with               
2-aminobenzimidazole.  Thus,  corresponding  five  membered  imidazobenzimidazolone  and  six 
membered pyrimidobenzimidazolone derivatives were exclusively isolated and characterized. 
 
Results and Discussion 
 
When cyanoepoxides 1 are heated under reflux with 2-aminobenzimidazole in acetonitrile 
solution  for  20  hours,  1,3-dihydro-3-aryl  imidazo[1,2-a]benzimidazol-2-ones  4  are  formed  in 
good yields (Table 1). The reaction proceeds by the initial attack of the imino ring nitrogen of the 
2-aminobenzimidazole to the carbon  to the nitrile groups.  
The  instable  cyanohydrin  loses  hydrogen  cyanide  giving  intermediate  acyl  cyanide,  leading 
immediately to imidazobenzimidazol-2-ones 4 through heterocyclization type reaction.  
In this reaction, the two carbons of epoxide 1 act as potential electrophilic centers (Scheme 1). 
The results obtained from the IR, 
1H NMR, and 
13C NMR data as well as the mass spectra are in 
agreement with the assigned structures 4. 
 
 
 
Scheme 1. Mechanism of the formation of imidazo[1,2-a]benzimidazol-2-ones 4. 
 
 
Table 1: Prepared imidazo[1,2-a]benzimidazol-2-ones 4. 
Substrate    Ar       Product    Yield  (%)
a   mp (°C)    
1a     C6H5                  4a      80   185-187   
1b      4-MeC6H4           4b      81   195-197   
1c      4-ClC6H4            4c      83   240-242   
1d      4-NO2C6H4           4d      78   224-226   
a Yields of  purified products after their  recrystallization in EtOH.  Mediterr.J.Chem., 2011, 1(1),  A. Zarguil et al.    32 
 
 
Pyrimidobenzimidazoles have been found to be of pharmacological  interest.  For  example 
pyrimido[1,2-a]benzimidazoles  have  been  described  as  antihypertensives,  antidiabetics, 
antiinflammatory  agents,  antirheumatics  and  as  antibiotics  against  staphylococcus  and 
mycobacterium ranae. They have antiarrythmic effects, herbicidal activity, antidepressant effects, 
microfilaricidal and macrofilaricidal effects, they act as bactericides, fungicides, virucides and as 
diuretics
21. 
These  findings  prompted  us  to  design  compounds  with  near  structural  relationship  to 
pyrimido[1,2-a]benzimidazoles for further pharmacological tests. 
As  part  of  our  study  using  the  epoxide  as  the  starting  material  for  the  preparation  of 
pyrimidobenzimidazoles,  we  have  designed  a  simple  method  for  the  synthesis  of               
pyrimidobenzimidazol-2,3-diones  by  the  reaction  of  epoxide  cyanoesters  2  with  the                        
2-aminobenzimidazole.  
Thus, treatment of 2 with 2-aminobenzimidazole, in equimolecular amounts, in acetonitrile 
under reflux, afforded products identified as the 1,2-dihydro pyrimido[1,2-a]benzimidazol-2,3-
diones 5 (Scheme 2, Table 2).  
 
Although  the  synthetic  methods  of  pyrimido[1,2-a]benzimidazoles  derivatives  are  well 
documented,  the  methods  for  the  synthesis  of  1,2-dihydro  pyrimido[1,2-a]benzimidazol-2,3-
diones 5 are limited.   
The  scheme  2  proposes  a  mechanism  which  shows  the  formation  of  pyrimido[1,2-
a]benzimidazol-2,3-diones 5.  
This reaction was interpreted by an initial opening of the epoxide 2 by a nucleophilic attack of 
the imino ring nitrogen on the carbon related to the aryl group. The formed intermediate loses a 
molecule of hydrocyanic acid and leads to cyanoformyl intermediate. The latter undergoes an 
heterocyclization reaction to give the pyrimido[1,2-a]benzimidazol-2,3-diones 5.   
 
 
 
 
Scheme 2. Route to pyrimido[1,2-a]benzimidazol-2,3-diones 5. Mediterr.J.Chem., 2011, 1(1),  A. Zarguil et al.    33 
 
 
The  regioselectivity  of  the  formed  product  formation  was  observed  on  the  level  of  the 
electrophilic  sites  of  attack  which  are  carbons  of  epoxide.  In  effect,  carbon  related  to  the 
grouping aryl is proven to be most electrophilic of the cycle.  In our laboratory, it has been 
demonstrated  that  the  epoxide  is  acting  as  a  synthon  type  .  The  strong 
nucleophilicity of the ring nitrogen imino compared with nitrogen of the amine function explains 
the selectivity on the level of the nucleophilic attack on epoxide. 
 
Table 2: Preparation of  pyrimidobenzimidazol-2,3-diones 5. 
Entry    Ar       R    Product    mp (°C)   Yield
a  % ( )
b  
a     C6H5            Et          5a      › 260    80 (76) 
b     4-MeC6H4         Et      5b      240-242  84 (81) 
c    4-ClC6H4          Et      5c      245-247  81 (80)   
d     4-MeC6H4         Me         5b      234-236  80 (76) 
e    4-ClC6H4          Me     5c       245-247  82 (80) 
f    4-NO2C6H4         Me     5d      254-256  70 (75) 
a Yields of  purified products after their recrystallization in  EtOH.  
b Yields obtained from halohydrins 3   
 
The halohydrins 3
22 are readily accessible in regioselective form, employing the ring opening 
reaction of epoxides esters 2 by halohydric acids. 
Indeed,  halohydrins  with  hydroxy,  cyano  and  ester  groups  on  the  same  carbon  atom  have 
synthetic  value  because  they  are  interesting  starting  materials  for  some  useful  synthetic 
transformation
23.   
 
These  conditions  led  us  to  imagine  that  the  reaction  of  these  halohydrins  with  the                                 
2-aminobenzimidazole could constitute respectively a new route to pyrimido[1,2-a]benzimidazol-
3,4-dione isomer of the pyrimido[1,2-a]benzimidazol-2,3-dione 5.      
However, it is also important to mention that when halohydrins 3 were used in this reaction, 
under  the  same  conditions  described  above,  the  same  isomer  1,2-dihydro  pyrimido[1,2-
a]benzimidazol-2,3-dione 5 was also obtained (Scheme 3, Table 2).  
 
The regioselectivity of the reaction was preserved. We found that this reaction is not efficient 
(see table 2) that the direct reaction of 2-aminobenzimidazole with epoxides 2, but it served to 
compare compounds of type 5 from the two reactions.  
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Scheme 3. Synthesis of  5 starting from halohydrins 3 as substrate. 
 
The  structures  of  all  new  compounds  5  were  appropriately  established  by  the  usual 
spectroscopic methods.
 
The determination of the structure 5 was also confirmed in agreement with 
1H NMR data in 
accord with the results published by Elnagdi and Wamholf
24.
 
Indeed, it has been shown that the hydrogen in position 6 of the core tricyclic benzene system 
resonates with the downfield (8.33 to 8.52 ppm) when its position is perished from the amide 
carbonyl. This deshielding is due to the magnetic anisotropy induced by the carbonyl of the 
pyrimidine ring. 
 
Conclusion 
 
In summary, we have developed a short, practical, and simple method for the synthesis of 
novel  imidazo[1,2-a]benzimidazol-2-ones  and  pyrimido[1,2-a]benzimidazol-2,3-diones 
derivatives from epoxides 1 or 2, resulting in promising substrates for drug design. Moreover, our 
new route seems of interest to us and compares favorably with existing methods. The biological 
interest and the study by X-ray of compounds mainly obtained in these experiments are under 
investigation.  
 
Experimental Section 
 
Melting points were taken on a KOFLER hot stage apparatus and are uncorrected. The 
1H NMR 
spectra were measured in dimethyl sulfoxide-d6 or (DMSO-d6) solutions on a Brucker 300 MHz 
spectrometer using TMS as an internal reference (chemical shift in  ppm), 
13C NMR spectra 
were recorded at 75 MHz. Infrared spectra were determined with a PERKIN ELMER 1600 Series 
FT-IR Spectrometer using KBr pellets. Mass spectra were recorded on a Thermo DSQII-Focus 
mass Spectrometer.  
 
Epoxides  1  or  2  were  prepared  in  a  two-step  procedure:  the  first  one,  a  Knoevenagel-Cope 
condensation. The second step, a stereospecific epoxidation of olefin by sodium hydrochlorite
25.
 
 
General procedure for synthesis of halohydrin 3 
To a solution of chlorhydric acid (14 mL) in diethyl ether (10 mL), epoxides cyanoesters 2 (10 
mmol) dissolved in diethyl ether (10 mL) were added dropwise at 25 °C. The reaction mixture 
was stirred at this temperature for 5h. The mixture was shaken with cold water (50 mL) and Mediterr.J.Chem., 2011, 1(1),  A. Zarguil et al.    35 
 
extracted. The combined organic extracts were washed with water and finally dried over Na2SO4. 
After evaporation of the solvent, the chlorohydrins 3 were recrystallized from CCl4. 
 
General procedure for synthesis of imidazo[1,2-a]benzimidazol-2-ones 4a-d 
To  a  solution  of  epoxide  1  (5  mmol)  in  acetonitrile  (20  mL),  were  added  the  2-
aminobenzimidazole  (5  mmol).  The  mixture  was  then  refluxed  for  24  h.  The  solvent  was 
removed under reduced pressure and the crude product was treated with a mixture of ether / 
petroleum ether, the imidazo[1,2-a]benzimidazol-2-ones 4a-d (Table 1) precipitate slowly and 
were recrystallized from EtOH. 
 
3-phenyl imidazo[1,2-a]benzimidazol-2-one (4a): Yield: 80%; mp: 185-187 °C.  
IR (KBr): 1722, 3320 cm
-1. 
1H NMR (DMSO-d6) (ppm): 6.80-7.20 (m, 9H, Ar), 5.47 (s, 1H, 
CH), 8.22 (s, 1H, NH). 
13C NMR (DMSO-d6) 108.1, 111.0, 115.5, 117.2, 120.5, 126.6, 128.4, 
129.3, 130.1, 134.7, (Ar-C), 155.2 (C=N), 165.0 (C=O), 55.4 (CH). MS m/z (%):  249 (M
+., 20), 
221 (M
+.-CO, 100), 206 (M
+. -HNCO, 40).   
3-(4-methyl phenyl) imidazo[1,2-a]benzimidazol-2-one (4b): Yield: 81%; mp: 195-197 °C.  
IR (KBr): 1720, 3319 cm
-1. 
1H NMR (DMSO-d6)  (ppm): 6.84-7.15 (m, 8H, Ar), 2.20 (s, 3H, 
CH3), 5 .45 (s, 1H, CH), 8.20 (s, 1H, NH). 
13C NMR (DMSO-d6) 109.2, 112.0, 117.5, 119.8, 
121.9, 127.8, 129.7, 130.4, 131.1, 138.7, (Ar-C), 155.4 (C=N), 165.1 (C=O), 21.6 (CH3), 55.4 
(CH). MS  m/z (%): 263 (M
+., 23), 235 (M
+.-CO, 100), 220 (M
+. - HNCO, 45).  
3-(4-chloro phenyl) imidazo[1,2-a]benzimidazol-2-one (4c): Yield: 83%; mp: 240-242 °C. 
IR (KBr):  1715, 3320 cm
-1. 
1H NMR (DMSO-d6) (ppm): 7.14-7.40 (m, 8H, Ar), 5.43 (s, 1H, 
CH), 8.23 (s, 1H, NH). 
13C NMR (DMSO-d6) 110.2, 110.1, 118.7, 120.5, 124.9, 128.8, 131.2, 
132.3, 134.8, 140.5, (Ar-C), 156.2 (C=N), 165.4 (C=O), 55.6 (CH). MS  m/z (%): 283 (M
+., 20), 
255 (M
+. - CO, 100), 240 (M
+. - HNCO, 48).  
3-(4-nitro phenyl) imidazo[1,2-a]benzimidazol-2-one (4d): Yield: 78%; mp: 220-222 °C. 
 IR (KBr): 1720, 3320 cm
-1. 
1H NMR (DMSO-d6)  (ppm): 7.16-7.44 (m, 8H, Ar), 5.44 (s, 1H, 
CH), 8.24 (s, 1H, NH). 
13C NMR (DMSO-d6) 110.6, 110.5, 118.8, 120.7, 125.2, 129.1, 131.5, 
132.7, 135.5, 141.5, (Ar-C), 156.2 (C=N), 165.4 (C=O), 55.6 (CH). 
 
Preparative procedure for synthesis of pyrimido[1,2-a]benzimidazol-2,3-diones 5a-d 
Epoxide 2 or halohydrin 3 (5 mmol) was dissolved in acetonitrile (20 mL), and the 2-amino 
benzimidazole was added (5 mmol). The mixture was refluxed, stirring constantly for 24 h. After 
evaporation of the solvent under reduced pressure, the precipitate pyrimido[1,2-a]benzimidazol-
2,3-diones 5a-d were recrystallized from EtOH. 
 
4-phenyl pyrimido[1,2-a]benzimidazol-2,3-diones (5a): Yield: 80%; mp: › 260 °C. 
 IR (KBr): 1722, 1700, 3260 cm
-1. 
1H NMR (DMSO-d6) (ppm):7.06-7.35 (m, 9H, Ar), 5.41 (s, 
1H, CH), 8.54 (s, 1H, NH). 
13C NMR (DMSO-d6) 107.4, 115.2, 121.2, 124.5, 127.1, 128.2, 
136.1, 137.2, 139.3 (C-Ar) 152 .1 (C=N), 165.4 (CO), 175.1 (CO), 61.9 (CH). MS m/z (%): 278 
(M
+. + 1, 100), 174 (55), 134 (35).   
4-(4-methyl phenyl) pyrimido[1,2-a]benzimidazol-2,3-diones (5b): Yield: 84%; mp: 240-242 °C.  
IR (KBr): 1720, 1700, 3257 cm
-1. 
1H NMR (DMSO-d6)   (ppm):7.12-7.42 (m, 8H, Ar), 5.40 
(s, 1H, CH), 8.56 (s, 1H, NH), 2.31 (s, 3H, CH3). 
13C NMR (DMSO-d6) 111.7, 117.5, 123.2, Mediterr.J.Chem., 2011, 1(1),  A. Zarguil et al.    36 
 
126.9, 129.4, 130.2, 136.7, 139.1, 140.3 (C-Ar) 152 .0 (C=N), 165.8 (CO), 175.5 (CO), 62.0 
(CH), 21.3 (CH3). Ms m/z (%): 292 (M
+. + 1, 100), 174 (60), 134 (30).    
4-(4-chloro phenyl) pyrimido[1,2-a]benzimidazol-2,3-diones (5c): Yield: 81%; mp: 254-256 °C.  
IR (KBr): 1722, 1700, 3250 cm
-1. 
1H NMR (DMSO-d6)  (ppm):7.20-7.53 (m, 8H, Ar), 5.42 (s, 
1H, CH), 8.52 (s, 1H, NH). 
13C NMR (DMSO-d6) 112.3, 118.4, 124.2, 127.2, 130.5, 131.2, 
136.2, 139.5, 142.1 (C-Ar), 152 .4 (C=N), 165.2 (CO), 168.3 (CO), 62.1 (CH). MS m/z (%): 312 
(M
+. + 1, 100), 174 (50), 134 (40). 
4-(4-nitro phenyl) pyrimido[1,2-a]benzimidazol-2,3-diones (5d): Yield: 70%; mp: 250-252 °C. 
 IR (KBr): 1720, 1703, 3253 cm
-1. 
1H NMR (DMSO-d6) (ppm):7.03-7.30 (m, 8H, Ar), 5.42 (s, 
1H, CH), 8.52 (s, 1H, NH). 
13C NMR (DMSO-d6) 106.3, 115.2, 121.1, 123.8, 126.4, 127.8, 
135.5, 137.1, 139.1 (C-Ar) 152 .2 (C=N), 165.2 (CO), 175.3 (CO), 62.1 (CH). MS m/z (%): 322 
(M
+., 100), 174 (55), 134 (35).  
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